-
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med
Tuesday, June 1, 2021 - 9:35am | 153Read More...The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity, for schizophrenia and bipolar I disorder. The approval comes as a maintenance...
-
BioXcel's Formulated Dexmedetomidine US Application For Agitation Under FDA Review
Wednesday, May 19, 2021 - 8:11am | 206Read More...The FDA has accepted for review, BioXcel Therapeutics Inc's (NASDAQ: BTAI) marketing application for BXCL501, an orally dissolving thin film formulation of dexmedetomidine. The application covers the acute treatment of agitation associated with schizophrenia and bipolar...
-
Minerva Shares Surge As Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning
Wednesday, May 12, 2021 - 6:59am | 283Read More...Minerva Neurosciences Inc (NASDAQ: NERV) has announced results from the 40-week open-label extension (OLE) of its Phase 3 trial evaluating roluperidone for the treatment of negative symptoms (NS) of schizophrenia. Over the 40-week OLE period, 333 patients participated. 166...
-
Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results
Monday, April 26, 2021 - 9:21am | 258Read More...Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has announced the full details of its Phase 2 trial evaluating its lead drug candidate, RP5063 (brilaroxazine), for Acute Schizophrenia. Brilaroxazine demonstrated high affinity and selectivity for key serotonin receptors (5-HT1A/2A...
-
Neurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity
Tuesday, March 2, 2021 - 9:53am | 282Read More...Neurocrine Biosciences Inc (NASDAQ: NBIX) announces topline data from Phase 2 INTERACT study evaluating luvadaxistat (NBI-1065844/TAK-831) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia. Luvadaxistat is an oral, selective inhibitor...
-
UPDATE: JMP Securities Initiates Coverage On Intra-Cellular Therapies
Tuesday, December 23, 2014 - 10:43am | 120Read More...Jason Butler of JMP Securities initiated coverage of Intra-Cellular Therapies (NASDAQ: ITCI) on Tuesday with a Market Outperform rating and $26 price target. “Intra-Cellular Therapies is focused on the development of ITI-007, a novel antipsychotic candidate currently in Phase 3 development for the...
